Tumor associated macrophages as key contributors and targets in current and future therapies for melanoma
S Habib, G Osborn, Z Willsmore, MW Chew… - Expert Review of …, 2024 - Taylor & Francis
Introduction Despite the success of immunotherapies for melanoma in recent years, there
remains a significant proportion of patients who do not yet derive benefit from available …
remains a significant proportion of patients who do not yet derive benefit from available …
[HTML][HTML] Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
CM Failla, ML Carbone, C Ramondino, E Bruni… - Biomedicines, 2024 - mdpi.com
The vascular endothelial growth factor (VEGF) family includes key mediators of
vasculogenesis and angiogenesis. VEGFs are secreted by various cells of epithelial and …
vasculogenesis and angiogenesis. VEGFs are secreted by various cells of epithelial and …
Sunitinib-induced endocapillary proliferative glomerulonephritis with IgA2 deposit in addition to thrombotic microangiopathy: a case report
X Zhang, H Wang, J Li, F Zhou, M Zhao, T Su - BMC nephrology, 2024 - Springer
Background Sunitinib, a multi-targeted tyrosine kinase inhibitor, is used as a second-line
therapy for gastrointestinal stromal tumors (GIST) resistant to imatinib. However, its impact …
therapy for gastrointestinal stromal tumors (GIST) resistant to imatinib. However, its impact …